Swedish Orphan Biovitrum AB (publ), known as Sobi, reported 357,636,514 common shares and the same number of votes as of 30 September 2026. The increase followed the issue of 223,677 class C shares for commitments under its long-term incentive programme for permanent employees, the All Employee Programme. Under a conversion clause in Sobi’s articles of association, the class C shares were converted into common shares. Sobi held 9,631,955 common shares as of the same date. The global biopharma company has approximately 2,000 employees, reported 2025 revenue of SEK 28 billion and is listed on Nasdaq Stockholm under STO: SOBI.